Abstract
Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Current Drug Targets
Title: A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia
Volume: 7 Issue: 9
Author(s): U. Taksh
Affiliation:
Keywords: Tardive dyskinesia, rating scales, anti-psychotics, movement disorder, schizophrenia
Abstract: Tardive dyskinesia (TD) has been recognised for nearly 50 years. It is associated with antipsychotic drugs and is usually persistent with no satisfactory treatment. It is believed to be under-documented in medical records. Many rating scales have been devised to measure TD. Studies have demonstrated variability between the rating scales on the measures of reliability and validity, the clinical setting used, the raters involved in the ratings and the provision of definitions and instructions. Scales that include too many items to be comprehensive become cumbersome and difficult to use. A compromise is to reduce the number of items and have add-in items for individual patients. A good example of this approach is the Abbreviated Dyskinesia Scale (ADS). Rating scales continue to be the best available methods to evaluate dyskinesia but in view of the shortcomings of validity, reliability and utility for clinical use, more efforts need to be done to improve current rating scales and to develop new ones.
Export Options
About this article
Cite this article as:
Taksh U., A Critical Review of Rating Scales in the Assessment of Movement Disorders in Schizophrenia, Current Drug Targets 2006; 7 (9) . https://dx.doi.org/10.2174/138945006778226589
DOI https://dx.doi.org/10.2174/138945006778226589 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant Therapeutic Approaches Toward Amelioration of the Pulmonary Pathophysiological Damaging Effects of Ionizing Irradiation
Current Respiratory Medicine Reviews Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Influence of Cytoplasmatic Folding on Mitochondrial Import
Current Medicinal Chemistry The Association of Hot/Cold Status of Temperament with Depression and Hopelessness Scores in Females
Current Traditional Medicine Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Role of Resveratrol and its Analogues in the Treatment of Neurodegenerative Diseases: Focus on Recent Discoveries
CNS & Neurological Disorders - Drug Targets Human Ether-a-Go-Go-Related Gene Channel Blockers and its Structural Analysis for Drug Design
Current Drug Targets Creatine Supplementation: Can it Improve Quality of Life in the Elderly without Associated Resistance Training?
Current Aging Science Aerobic Exercise for Preventing Osteoporosis in Postmenopausal Women: an Update of its Effect on Bone Mineral Density
Current Rheumatology Reviews Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Discovery of Novel Regulatory Peptides by Reverse Pharmacology: Spotlight on Chemerin and the RF-amide Peptides Metastin and QRFP
Current Protein & Peptide Science Intracellular Signaling and Approaches to the Treatment of Schizophrenia and Associated Cognitive Impairment
Current Pharmaceutical Design Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Role of Vitamins in Neurodegenerative Diseases: A Review
CNS & Neurological Disorders - Drug Targets Monoaminergic Neurotransmission: The History of the Discovery of Antidepressants from 1950s Until Today
Current Pharmaceutical Design Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases
Current Pharmaceutical Design